Five things for pharma marketers to know: Wednesday, May 30, 2018

Share this content:

Allergan has decided to sell its women's health and infectious disease units, according to a report. The company is trying to bring up its share price, which has fallen 32% over the last 12 months, and refocus on core areas. Analysts have valued the women's health business at $4 billion and the infectious disease business at $2 billion. (CNBC)


Big clinical trials are falling out of favor. Instead, researchers are turning to smaller, more narrowly targeted clinical trials to test medicines. However, experts are divided over whether smaller trials are better. They make sense in an era of personalized medicine, but miss the large amounts of data from larger trials. (Wall Street Journal)


The American Cancer Society has recommended screening for colon cancer at age 45, not 50. The society's chief cancer control officer cited a sharp increase in deaths from colon and rectal cancers among men and women under age 50 and the increasing risk of developing colon and rectal cancer for the change. (NPR)


The FDA has reversed a previous decision on TherapeuticsMD's therapy for pain during sex, Imvexxy. Last year, the FDA rejected the therapy, but dropped its complete response letter shortly after Commissioner Scott Gottlieb joined the FDA, raising concerns over political influence over the reversal. The drug was approved on Wednesday. (Endpoints)


Allergan is recalling birth control pills packaged in the wrong order. A doctor reported that the placebo pills for Allergan's Taytulla were placed in the wrong order of the pill pack. Allergan is recalling the pills because “oral contraceptive capsules that are taken out of sequence may place the user at risk for contraceptive failure and unintended pregnancy," Allergan said in a statement. (CNN)


Share this content:
Scroll down to see the next article